OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
May 04, 2023
Presspart will still be responsible for the manufacturing of the Sunriser device.
March 23, 2023
Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.
March 17, 2023
Polyplus’ LipidBrick is designed to expand the scope of lipid nanoparticle formulation usage in mRNA therapeutics and vaccine development.
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.
December 14, 2022
Particle engineering can be a resourceful tool to advance drug candidates by offering drug delivery innovation.
November 08, 2022
Companies need to consider and address formulation challenges to employ a successful reformulation strategy.
October 02, 2022
There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too.
September 16, 2022
Research into oncolytic viruses potentiated by stem cells shows promise for treating cancer.
Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.
September 15, 2022
Using an orthogonal approach to lipid nanoparticle analysis can increase the odds of project success.